Roche: leukaemia combo improves progression-free survival

(CercleFinance.com) - A combination of drugs belonging to Roche's portfolio improved the conditions of patients living with chronic lymphocytic leukaemia, according to a late-stage study presented on Wednesday.


In a phase III trial, Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions, the Swiss drugmaker said.

At two years, one year after stopping treatment, nearly nine out of ten patients (88.2%) in the Venclexta/Venclyxto plus Gazyva/Gazyvaro arm remained progression-free, compared to 64.1% in the Gazyva/Gazyvaro plus chlorambucil arm, it said.

Copyright (c) 2019 CercleFinance.com. All rights reserved.